|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF inhibitors showed activity in BRAF V600E mutated cholangiocarcinomas and pancreatic carcinomas in non-first line settings.
|
31221175 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
LLS carcinomas were diagnosed at a mean age of 65 years (vs. 44 years in LS, p < 0.001), had a proximal to distal ratio of 1:1, and all were BRAF V600E-negative.
|
30575961 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy.
|
28006055 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Few authors demonstrated that some architectural and specific cellular findings (i.e. polygonal eosinophilic cells defined as "plump cells" and sickle-shaped nuclei) are able to predict BRAF V600E mutation in both cytological and histological samples of papillary thyroid carcinoma (PTC) as well as in other carcinomas.
|
27738305 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The vast majority of the BRAF V600E mutations were found in cerebral metastases of malignant melanomas and carcinomas (29/135, 22 %), with false-positive staining found in four breast cancer cases and two non-small-cell lung carcinoma (NSCLC) samples.
|
27350555 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis.
|
24832158 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found BRAF V600E mutations in 13% (4/31) of serous LMP and 5% (3/62) of invasive serous carcinomas.
|
22820660 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Importantly, expression of BRAF(V600E) concomitant with the loss of only a single-copy of Lkb1, overcomes senencence-like features of BRAF(V600E)-mutant adenomas leading malignization to carcinomas.
|
23825589 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.
|
23354848 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The high frequency of methylation and BRAF V600E mutation suggests that many signet ring cell carcinomas may be related to the serrated pathway of carcinogenesis.
|
22522845 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed 29 gallbladder carcinomas (9 papillary and 20 nonpapillary adenocarcinomas), 16 adenomas (6 pyloric, 3 intestinal, 3 biliary, 3 mixed pyloric-biliary, and 1 mixed pyloric-intestinal), and 5 cases of high-grade dysplasia for activating missense mutations in KRAS codons 12 and 13 and BRAF V600E mutations.
|
21307665 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The development of BRAF(V600E)transgenic mice with the MST1 knockout background showed that these mice had abundant foci of poorly differentiated carcinomas and large areas without follicular architecture or colloid formation.
|
21249150 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in 36.3% of SCa and 26.7% of TSA patients, but it was not detected in TA and Ca patients; MSI-H was noticed in 23% of SCa, 33.3% of TSA, 5.3% of Ca and 0% of TA patients, respectively (P<0.05).
|
21615873 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In contrast to other Braf-induced mouse models of tumorigenesis (i.e., melanomas and lung), in which knock-in of Braf(V600E) induces mostly benign lesions, Braf-expressing thyrocytes become transformed and progress to invasive carcinomas with a very short latency, a process that is dampened by treatment with an allosteric MEK inhibitor.
|
21220306 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Congruently, 0/10 oncoAd and 0/20 oncoFTC described in the literature so far carried BRAF V600E mutations.
|
18235983 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas and 33% (5/15 cases) of undifferentiated carcinomas but not in normal thyroid tissues, nodular hyperplasia, follicular adenomas, or follicular carcinomas.
|
17714762 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas.
|
17309670 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
|
17453004 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The B-Raf gene was mutated with a T-->A transversion at nucleotide 1799 (V600E) in 8 of 10 differentiated PTC, and in 4 of 7 aggressive carcinomas.
|
16676402 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF mutations were detected exclusively in papillary carcinomas (40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas.
|
14508525 |
2003 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The prevalence of the BRAF(V599E) mutation in PTC is the highest reported to date in human carcinomas, being only exceeded by melanoma.
|
12881714 |
2003 |